Critics think Johnson & Johnson got off relatively easy when the company agreed ... The big settlement did not appear to perturb the market, as the company's stock price dropped less than a dollar after the announcement and then ended …
Johnson & Johnson (NYSE: JNJ) is a healthcare giant that sells over-the-counter products, pharmaceuticals, and medical devices. Its diversification makes it a core holding for many investors, including income investors who love its …
Johnson & Johnson trained its employees to reassure anyone concerned ... J&J was little changed at $131.81 in New York Stock Market composite trading at 11:19 a.m. Lawyers representing the women can use the documents in court …
Johnson & Johnson innovation has opportunity to take ownership interest in co through common stock purchase warrant issued by co to JJDC . JJDC can take ownership interest in co through common stock purchase warrant issued by co …
Billionaire Warren Buffett's Berkshire Hathaway Inc reduced stakes in health-care company Johnson & Johnson and consumer products company ... five months to buy convertible securities, preferred stock and debt issued by General …
And it's no surprise to see the stock trading at a fresh 52-week high in response. Steve Symington has no position in any of the stocks mentioned. The Motley Fool recommends Planet Fitness. The Motley Fool has a disclosure policy. As a …
Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced a reverse stock split of its shares of common stock
The stock has increased 65 percent in the last 12 months. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EBS …
Johnson&Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $143.80 to a high of $147.44. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $145.97 on volume of 5.0 million …
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.